Follow-On Protein Products: What, Where, When, How?

Therapeutic Monoclonal Antibodies: From Bench to Clinic

Volumn , Issue , 2009, Pages 763-777

  Williams, Brent R ^a   Strohl, William R ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CENTOCOR INC   (United States)

Author keywords

Currently marketed FOPPs human growth hormone and erythropoietin; Europe and United States regulatory landscape; Scientific and regulatory issues associated with generic protein therapeutics

Indexed keywords

EID: 84890974900     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470485408.ch32     Document Type: Chapter

References (29)

1. Boven, K., J. Knight, F. Bader, J. Rossert, K.U. Eckardt, and N. Casadevall. 2005. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: Solving the mystery. Nephrol. Dial. Transplant. 20 (Suppl 3): 33-40.
2. Budget of the United States Government, Fiscal Year 2009. 2008. Washington, D.C.: U.S. Government Printing Office.
3. Committee for Medicinal Products for Human Use. 2005. Guideline on Similar Biological Medicinal Products-CHMP/437/04. London: European Medicines Agency.
4. Committee for Medicinal Products for Human Use. 2006a. Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues-Guidance on Similar Medicinal Products Containing Somatropin-EMEA/CHMP/BMWP/94528/2005. London: European Medicines Agency.
5. Committee for Medicinal Products for Human Use. 2006b. Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues-Guidance on Similar Medicinal Products Containing Erythropoietins-EMEA/CHMP/BMWP/94526/2005 Corr. London: European Medicines Agency.
6. Datamonitor. 2007. Biosimilars Series: Strategic Issues; Potential Remains Uncertain. New York: Datamonitor USA.
7. Dr. Reddy's Laboratories Ltd. 2007. Dr. Reddy's Launches Reditux: Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma. Available at http://www.drreddys.com/newsroom/2007yrnews.htm# (accessed March 24, 2008).
8. FDA/Center for Drug Evaluation and Research. 1999. Guidance for Industry: Applications Covered by Section 505(b)(2) (Draft). Available at http://www.fda.gov/CDER/guidance/2853dft.htm#P109_2037 (accessed January 10, 2008).
9. FDA/Center for Drug Evaluation and Research. 2006. Frequently Asked Questions About Therapeutic Biological Products. Available at http://www.fda.gov/cder/biologics/qa.htm (Accessed January 10, 2008).
10. FDA/Center for Drug Evaluation and Research. 2008. What Are Generic Drugs. (available at http://www.fda.gov/cder/ogd (accessed January 10, 2008).
11. Generic Pharmaceutical Association. 2008. Generics: Lower Cost. Available at http://www.gphaonline.org/AM/Template.cfm?Section=FAQs&Template=/CM/HTMLDisplay.m&ContentID=2497 (accessed January 10, 2008).
12. GovTrack.us. 2007. S. 1695-110th Congress. Biologics Price Competition and Innovation Act of 2007. Available at http://www.govtrack.us/congress/bill.xpd?bill=s110-1695 (accessed January 10, 2008).
13. Grabowski, H., I. Cockburn, G. Long, R. Mortimer, and S. Johnson. 2007. The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions. White Paper. Available at http://www.bio.org/healthcare/followonbkg/Federal_Spending_of_followonbkg200709. pdf (accessed January 10, 2008).
14. Haas, J.S., K.A. Phillips, E.P. Gerstenberger, and A.C. Seger. 2005. Potential savings from substituting generic drugs for brand-name drugs: Medical expenditure panel survey, 1997-2000. Ann. Intern. Med. 142:891-897.
15. Health Products and Food Branch. 2008. Draft Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics. Ottawa: Health Canada.
16. Hofelich, A. 2006. GPhA Hails Introduction of Legislation to Bring Affordable Generic Biopharmaceutical Medicines to Consumers. Available at http://www.gphaonline.org/AM/PrinterTemplate.cfm?Section= Media&Template=/CM/HTMLDisplay.cfm&ContentID=2849 (accessed January 10, 2008).
17. Joung, J., J.S. Robertson, E. Griffiths, and I. Knezevic. 2008. WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, April 19-20, 2007. Biologicals 36:269-276.
18. Lin, F.K., inventor; Kiren-Amgen, Inc., assignee. 1996. Production of erythropoietin. U.S. patent 5,547,933. August 20, 1996.
19. Louet, S. 2003. Lessons from Eprex for biogeneric firms. Nature Biotechnol. 21:956-957.
20. Manheim, B.S., Jr., P. Granahan, and K.J. Dow. 2006. Follow-on biologics: Ensuring continued innovation in the biotechnology industry. Biotech Industry March/April, 394-404.
21. Marchant, J. 2007. The Future of Biosimilars. Key Opportunities and Emerging Therapies. London: Business Insights Ltd.
22. Mocini, D., T. Leone, M. Tubaro, M. Santini, and M. Penco. 2007. Structure, production and function of erythropoietin: Implications for therapeutical use in cardiovascular disease. Curr. Med. Chem. 14:2278-2287.
23. Moran, N. 2008. Fractured European market undermines biosimilar launches. Nature Biotechnol. 26:5-6.
24. Public Health Service Act. 2006. 42 U.S.C. 262.
25. Reymond, E. 2007. Dr. Reddy's launches Rituxan biosimilar in India. Breaking News on Drug Discovery. Available at http://www.drugresearcher.com/news/ng.asp?n=76261-dr-reddy-s-roche-biosimilars-india (accessed March 24, 2008).
26. Shapiro, R.J., K. Singh, and M. Mukim. 2008. The Potential American Market for Generic Biological Treatments and the Associated Costs Savings. Available at: www.insmed.com/pdf/Biogeneric_Savings.pdf (accessed August 14, 2008).
27. Woodcock, J. 2007. Statement of Dr. Janet Woodcock before the U.S. House of Representatives, March 26, 2007, "Follow-on Protein Products". Available at http://www.fda.gov/ola/2007/protein32607.html (accessed January 10, 2008).
28. Woodcock, J., J. Griffin, R. Behrman, B. Cherney, T. Crescenzi, B. Fraser, D. Hixon, C. Joneckis, S. Kozlowski, A. Rosenberg, L. Schrager, E. Shacter, R. Temple, K. Webber, and H. Winkle. 2007. The FDA's assessment of follow-on protein products: A historical perspective. Nature Rev. Drug Discov. 6:437-442.
29. World Health Organization. 2006. WHO Informal Consultation on International Nonproprietary Names (INN) Policy for Biosimilar Products. Available at http://www.who.int/medicines/services/inn/BiosimilarsINN_ReportSept2006.pdf (accessed March 24, 2008).